{
    "pmid": "41437610",
    "title": "[Rectosigmoid Colon Cancer with Unresectable Liver Metastases That Responded Remarkably to Bevacizumab-Combined Chemotherapy-A Case Report].",
    "abstract": "A woman in her 50s was referred to our hospital after a health checkup revealed a large liver tumor on abdominal ultrasonography. Colonoscopy revealed a Type 3 lesion occupying half of the rectosigmoid colon, and a biopsy confirmed a diagnosis of well-differentiated tubular adenocarcinoma. Contrast-enhanced computed tomography revealed multiple liver metastases in both lobes, and laparoscopic high anterior resection was performed(pT3N0M1a, Stage â…£). Post-operatively, chemotherapy was initiated with a single course of mFOLFOX6, followed by 11 courses of mFOLFOX6+bevacizumab. Due to worsening peripheral neuropathy, the regimen was switched to FOLFIRI+bevacizumab, which was administered over 43 courses. Although the liver metastases steadily reduced in size, the response remained as a partial response. Two years and 6 months after the initiation of chemotherapy, the patient elected to discontinue treatment, and follow-up observation was continued thereafter. Three years and 4 months after discontinuation of chemotherapy, the liver metastases continued to regress, suggesting a clinical complete response.",
    "disease": "colorectal cancer",
    "clean_text": "rectosigmoid colon cancer with unresectable liver metastases that responded remarkably to bevacizumab combined chemotherapy a case report a woman in her s was referred to our hospital after a health checkup revealed a large liver tumor on abdominal ultrasonography colonoscopy revealed a type lesion occupying half of the rectosigmoid colon and a biopsy confirmed a diagnosis of well differentiated tubular adenocarcinoma contrast enhanced computed tomography revealed multiple liver metastases in both lobes and laparoscopic high anterior resection was performed pt n m a stage post operatively chemotherapy was initiated with a single course of mfolfox followed by courses of mfolfox bevacizumab due to worsening peripheral neuropathy the regimen was switched to folfiri bevacizumab which was administered over courses although the liver metastases steadily reduced in size the response remained as a partial response two years and months after the initiation of chemotherapy the patient elected to discontinue treatment and follow up observation was continued thereafter three years and months after discontinuation of chemotherapy the liver metastases continued to regress suggesting a clinical complete response"
}